The tau protein aggregates in progressive supranuclear palsy (PSP) exhibit distinct morphological and molecular characteristics that differentiate them from other tauopathies such as Alzheimer's disease (AD) and corticobasal degeneration (CBD). Understanding these disease-specific properties is critical for developing targeted diagnostics and therapeutics, as tau pathology propagation appears to follow strain-specific mechanisms[@tau2025].
PSP is classified as a 4R-tauopathy, meaning it preferentially incorporates the four-repeat isoform of tau (4R-tau) in its aggregates, in contrast to AD which shows a mixture of 3R and 4R isoforms (3R+4R)[@muirhead2020]. This isoform composition difference fundamentally shapes the structural and biological properties of tau aggregates, influencing how they form, spread, and interact with cellular machinery. The distinct morphological features of PSP tau aggregates reflect this isoform preference and provide pathological confirmation of the diagnosis[@dickson2018].
Recent research using single-molecule assays, cryo-electron microscopy (cryo-EM), and super-resolution microscopy has revealed that PSP tau aggregates encode disease-specific mechanisms through their unique structural and biochemical properties. These advances have enabled unprecedented insights into the molecular basis of tauopathies and opened new avenues for disease-specific therapeutic development[@chen2024].
The tau protein aggregates in progressive supranuclear palsy (PSP) exhibit distinct morphological and molecular characteristics that differentiate them from other tauopathies such as Alzheimer's disease (AD) and corticobasal degeneration (CBD). Understanding these disease-specific properties is critical for developing targeted diagnostics and therapeutics, as tau pathology propagation appears to follow strain-specific mechanisms[@tau2025].
PSP is classified as a 4R-tauopathy, meaning it preferentially incorporates the four-repeat isoform of tau (4R-tau) in its aggregates, in contrast to AD which shows a mixture of 3R and 4R isoforms (3R+4R)[@muirhead2020]. This isoform composition difference fundamentally shapes the structural and biological properties of tau aggregates, influencing how they form, spread, and interact with cellular machinery. The distinct morphological features of PSP tau aggregates reflect this isoform preference and provide pathological confirmation of the diagnosis[@dickson2018].
Recent research using single-molecule assays, cryo-electron microscopy (cryo-EM), and super-resolution microscopy has revealed that PSP tau aggregates encode disease-specific mechanisms through their unique structural and biochemical properties. These advances have enabled unprecedented insights into the molecular basis of tauopathies and opened new avenues for disease-specific therapeutic development[@chen2024].
PSP tau aggregates demonstrate distinct morphological features compared to other 4R-tauopathies and Alzheimer's disease. These differences are observable at both light microscopy and electron microscopy levels and provide diagnostic clues for neuropathologists[@williams2022].
| Property | PSP | AD | CBD |
|----------|-----|----|-----|
| Shape | Shorter, round | Long, fibrillar | Variable |
| Length | Compact (40-80 nm) | Elongated (80-150 nm) | Intermediate |
| Structure | Granular | Paired helical filaments (PHFs) | Annular |
| Filament type | Predominantly straight | PHFs and straight | Mixed |
| Protofilaments | Typically 2 | 2-4 | 2-3 |
The shorter, rounder morphology of PSP aggregates reflects the predominant 4R tau isoform incorporation and the specific brain regions affected in PSP[@jellinger2023]. This morphological distinction has practical implications for diagnostic approaches using postmortem brain tissue and is increasingly relevant for ante-mortem biomarker development.
Electron microscopy studies reveal disease-specific ultrastructural characteristics that distinguish PSP tau from other tauopathies[@chen2024]:
The phosphorylation state of tau aggregates varies significantly between different tauopathies, providing both diagnostic biomarkers and insights into disease-specific kinase/phosphatase dysregulation[@kovacs2020].
Serine 356 (pS356):
The differential phosphorylation patterns likely reflect disease-specific patterns of kinase and phosphatase activity. In PSP, the enrichment of pS356 may indicate altered activity of specific kinases such as MARK/SAD or casein kinases, while reduced pT181 and pS396 compared to AD suggests relatively less glycogen synthase kinase 3-beta (GSK3β) activity in PSP[@hochfeld2023].
Within the 4R-tauopathy spectrum, PSP shows distinctive phosphorylation patterns from CBD and other 4R-tauopathies. CBD often shows more uniform phosphorylation across epitopes, while PSP demonstrates selective enrichment of specific sites. This distinction may reflect different upstream cellular stress pathways and provides a basis for developing disease-selective antibodies for immunotherapy applications[@kovacs2020].
One of the most significant discoveries in tauopathy research is the demonstration that tau aggregates can propagate in a prion-like manner, templates the conversion of endogenous tau into pathological forms. PSP tau aggregates demonstrate robust seeding activity that can propagate pathology in cellular and animal models[@tan2021].
Key observations supporting prion-like propagation in PSP[@arendt2018]:
The spread of tau pathology in PSP follows specific patterns that reflect both the route of propagation and the vulnerability of different cell types. Understanding these patterns is crucial for developing therapeutic interventions that prevent tau spread[@combs2021].
PSP tau aggregation involves several molecular pathways that can be targeted therapeutically. Understanding the sequence of events leading to aggregate formation is essential for developing prevention strategies[@peng2025].
Beyond phosphorylation, PSP tau undergoes additional post-translational modifications that influence its aggregation propensity and properties[@narasimhan2020].
Emerging evidence suggests that PSP, like other tauopathies, may involve multiple distinct tau strains that correlate with clinical phenotypes. This strain diversity has important implications for diagnosis and therapy development[@furhmann2022].
Tau strain diversity has profound implications for therapeutic development:
The morphological and biochemical characteristics of PSP tau aggregates provide pathological confirmation of diagnosis and differentiation from other tauopathies[@dickson2018].
These disease-specific properties inform biomarker development for ante-mortem diagnosis and disease monitoring[@williams2022].
Understanding PSP-specific tau properties enables targeted therapeutic development that exploits disease-specific vulnerabilities[@song2023].
Small molecule inhibitors:
Preventing the pathological spread of tau represents a key therapeutic strategy:
Several therapeutic approaches are being evaluated in PSP clinical trials:
| Approach | Target | Stage | Status |
|----------|--------|-------|--------|
| Anti-tau antibodies (Gosuranemab) | N-terminal tau | Phase 2 | Completed |
| Anti-tau antibodies (Bepranemab) | Mid-domain tau | Phase 2 | Recruiting |
| Tau ASO (NIO752) | Tau mRNA | Phase 1/2 | Active |
| 4R-tau ligand (E2814) | 4R-tau | Phase 2 | Recruiting |
| Microtubule stabilizer (Davunetide) | Tau function | Phase 3 | Completed |
Current research priorities include advancing our understanding of PSP tau at multiple levels[@chen2024]:
Key knowledge gaps remain in our understanding of PSP tau pathology:
The disease-specific morphology and molecular characteristics of tau aggregates in PSP provide critical insights into disease pathogenesis and offer opportunities for targeted diagnostics and therapeutics. The identification of pS356 as a PSP-enriched phosphoepitope, combined with the shorter, rounder aggregate morphology and straight filament predominance, distinguishes PSP from other tauopathies and informs the development of disease-specific approaches.
Understanding these aggregate properties is essential for advancing both basic research and clinical applications in PSP. The ongoing development of strain-typing assays, disease-selective antibodies, and targeting strategies based on PSP-specific tau properties represents a promising frontier in tauopathy therapeutics. As our understanding of tau strain diversity and propagation mechanisms continues to advance, the prospect of disease-modifying therapies for PSP becomes increasingly realistic.